GlassScriptPhysician profile
Philbert J Ford
NPI 1891711776
$11,539.56
in general payments reported to CMS, 2019-2025
13 companies · $427 in 2025
The $427 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,148 · 2020: $4,038 · 2021: $889 · 2022: $367 · 2023: $457 · 2024: $213 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069 · Education: $28.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.57 |
| Education | $28.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $9,578.35 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Shionogi INC | $393.55 | 2020-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $327.59 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $309.25 | 2021-2025 | |
| Gilead Sciences, INC. | $286.87 | 2019-2025 | |
| Theratechnologies INC. | $183.96 | 2019-2025 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $182.13 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $72.22 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $57.99 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $56.96 | 2022-2023 | |
| Allergan, INC. | $48.74 | 2019-2020 | |
| Melinta Therapeutics, LLC | $29.94 | 2022 | |
| Smith+Nephew, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philbert Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.